Ginkgo & OpenAI Slash Protein Synthesis Costs by 40%
Ginkgo Bioworks teams up with OpenAI to cut cell-free protein synthesis costs by 40% using AI and cloud lab automation.
Already have an account? Sign in.
Ginkgo Bioworks teams up with OpenAI to cut cell-free protein synthesis costs by 40% using AI and cloud lab automation.
NVIDIA’s September 2026 13F reveals a smaller $48.3B portfolio, led by SpaceX after a major reduction in its Intel stake from the prior quarter.
Rosemont aims to expand its U.S. specialty pharma presence.
Kalshi acquired a New York broker and plans to launch stock and ETF trading within two months, pressuring shares of Robinhood and Bullish.
Be the first to know when deals break, stocks move, or biotech headlines hit.